Agent | Neonates | Adults |
---|---|---|
Steroids | No evidence of improved outcome in critically ill infants or children with sepsis [89] | High-dose: no benefit [101] or reduction in mortality [102], may actually increase mortality [86] |
 |  | Hemodynamically stable: no benefit [101] |
 |  | Low-dose, long-course: may decrease mortality [87] |
Intravenous immunoglobulin | Prevention: 3% reduction in sepsis, 4% reduction in any serious infection; no change in mortality, necrotizing enterocolitis, bronchopulmonary dysplasia, intraventricular hemorrhage or length of stay [103] | Polyclonal: significant reduction in mortality [105] |
 | Suspected infection: decrease in mortality of borderline statistical significance [104] | Monoclonal: HA-1A, E5, IL-1, phospholipase A2, adhesion molecules and contact factors all show no benefit [86] |
 | Proven infection: no change in mortality [104] |  |
Colony-stimulating factors | Treatment: rhG-CSF and rhGM-CSF not effective in reducing mortality [106,107] | rhG-CSF in pneumonia with severe sepsis: no difference in mortality, ARDS or adverse events [108,109]; no difference in days of ventilatory support or intensive care unit stay [108] |
 | Prophylaxis: both agents effective in correcting neutropenia in premature neonates [106 107]; rhGM-CSF may decrease infection in infants <32 weeks who are neutropenic or at risk for developing neutropenia [106,107]; rhGM-CSF decreases mortality in neutropenic neonates with sepsis [107] | rhG-CSF in severe sepsis: small study shows a significant decrease in mortality [110] |
 |  | rhG-CSF febrile neutropenia: shorter hospital stay, no difference in mortality [111] |
 |  | rhGM-CSF in severe sepsis: no change in mortality [112,113]; improved PaO2/FiO2 ratio [112] and clearance of infection [113] |
Activated protein C | No randomized trials in neonates [114,115] | Severe sepsis and increased risk of death: improved organ function and decreased mortality [114]; 19.4% reduction in relative risk of death [84]; cost-effective [117] |
 | Two case reports with survival without adverse events [114,116] | Severe sepsis and low risk of death: no benefit [118] |
 | Large pediatric clinical trial stopped early due to no improvement in mortality and increased intracranial hemorrhage [98] |  |
Pentoxifylline | Decreased mortality, circulatory compromise, disseminated intravascular coagulopathy and necrotizing enterocolitis versus placebo [94] | Improved cardiopulmonary function [96] and hemodynamic performance [95] |
 | Reduces mortality without adverse effects [119] | No change in 28-day mortality [95] |
 |  | No adverse effects [95,96] |